Developer docs
API playgroundTry for free, no card

Search company profiles

Pangea Laboratory

Full company profile

uuid00097eb

Namestring
Pangea Laboratory
Legal namestring
Pangea Laboratory LLC
Websiteurl
pangealab.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Pangea Laboratory LLC is a CLIA-certified and CAP-accredited next-generation sequencing (NGS) and molecular diagnostics laboratory headquartered in Tustin, California, with an additional facility in Irvine. Founded in 2014 by Dr. Larry Jia — who also founded Zymo Research Corp and is credited with discovering the West Nile virus in North America — the company employs 101–250 people and operates as a private LLC. Its core technology stack combines NGS with multi-omics workflows, advanced bioinformatics, and AI/ML analytical tools for applications spanning epigenetics, microbiome analysis, and infectious disease.

The company serves three primary customer segments: clinicians and healthcare providers (oncologists, urologists, gastroenterologists, and primary care physicians) seeking precision diagnostic tests; researchers and academic institutions requiring high-throughput sequencing and validation; and pharmaceutical and diagnostic developers needing CLIA/CAP-grade analytical and clinical validation services. Its product portfolio includes proprietary laboratory developed tests (LDTs) — Bladder CARE™ (urine-based DNA methylation bladder cancer test with FDA Breakthrough Device Designation), iFOB (fecal immunochemical colorectal cancer screening with a reported 3.6%–5.1% false positive rate), and GA-map® MHI GutHealth (microbiome-based diagnostic licensed from Genetic Analysis AS) — alongside a forthcoming PrecisionBIOME™ NGS pathogen and antimicrobial resistance panel scheduled for Q2 2026. Strategic distribution is supported through partnerships with Unilabs (Bladder CARE™) and Gene Solutions (SPOT-MAS and K-4CARE liquid biopsy validation).

Pangea generates revenue through three primary streams: per-test transaction fees for laboratory testing services (CLIA/CAP reference lab work, iFOB, Bladder CARE™), professional services fees for clinical development and validation engagements with pharma and diagnostic developers, and licensing-equivalent economics from partnered LDT distribution. Pricing is quote-based and not publicly disclosed, though iFOB is positioned as substantially less expensive than colonoscopy or multi-target stool DNA alternatives (approximately 22× cheaper than Cologuard®). Go-to-market is primarily B2B enterprise field sales supported by digital marketing (website, LinkedIn, YouTube) and direct quote-based engagement with healthcare systems, hospital networks, and primary care physician groups. The company has no disclosed institutional investors, funding rounds, or revenue figures.

Short descriptiontext

Pangea Laboratory is a CLIA-certified, CAP-accredited next-generation sequencing and molecular diagnostics laboratory that provides clinical development services, reference lab work, and proprietary diagnostic tests to clinicians, researchers, and diagnostic developers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTustin, United States
HQ citystring
Tustin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics services, next-generation sequencing, clinical laboratory testing, cancer screening diagnostics, microbiome diagnostic testing
Industry4 codes
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics Laboratory Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Laboratory Testing Services
TypeTransaction Fee
Description

CLIA/CAP-accredited laboratory providing diagnostic testing services including custom sequencing solutions, reference lab services, and clinical validation testing. Revenue generated from test processing fees.

pangealab.com
2Clinical Development Services
TypeProfessional Services
Description

Transforming innovative research into validated, clinically actionable insights through validated NGS-based diagnostics and precision testing for external partners.

pangealab.com
3Diagnostic Products
TypeOne Time License
Description

Offering proprietary diagnostic tests including Bladder CARE™ for bladder cancer detection and iFOB for colorectal cancer screening as laboratory developed tests (LDTs).

pangealab.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Bladder CARE
Description

Urine-based DNA methylation test for bladder cancer detection, granted FDA Breakthrough Device Designation

pangealab.com
+3 more records
Core offering1 text field

Pangea Laboratory is a CLIA-certified and CAP-accredited Next-Generation Sequencing (NGS) diagnostic laboratory that delivers integrated services spanning custom sequencing solutions, clinical development, reference lab testing, and proprietary diagnostic assays. The company's menu includes Bladder CARE™ (urine-based DNA methylation bladder cancer test with FDA Breakthrough Device Designation), iFOB (fecal immunochemical colorectal cancer screening), GA-map® MHI GutHealth (microbiome-based gut health test), and PrecisionBIOME™ (NGS pathogen and antimicrobial resistance panel — coming Q2 2026). It serves clinicians, researchers, pharma companies, and diagnostic developers across oncology and infectious disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 90% of colorectal cancer patients survive when detected at early stage
+3 more records
Product overview1 text field

Pangea Laboratory is a CLIA-certified and CAP-accredited NGS diagnostic laboratory offering an integrated suite of services spanning clinical development, reference lab services, and diagnostic laboratory testing. The company's product portfolio includes proprietary tests: Bladder CARE™ (urine-based DNA methylation bladder cancer test with FDA Breakthrough Device Designation), iFOB (fecal immunochemical test for colorectal cancer screening), GA-map® MHI GutHealth (microbiome-based gut health test in partnership with Genetic Analysis AS), and PrecisionBIOME™ (NGS platform for pathogen detection - coming Q2 2026). The company also provides custom sequencing solutions and serves as a reference laboratory for research and clinical applications.

Product and service7 records
1Clinical Development Services
CategoryLaboratory Testing Services
Description

Translates innovative research into validated, clinically actionable insights through validated NGS-based diagnostics and precision testing, all within a CLIA/CAP environment. Targeted at diagnostic developers and pharma partners needing assay development, analytical and clinical validation.

2Reference Lab Services
CategoryLaboratory Testing Services
Description

High-throughput, high-quality sequencing and analysis services backed by rigorous quality controls and reproducible standards. Targeted at researchers, academic institutions, and clinicians needing reliable sequencing capacity.

3Diagnostic Laboratory Services
CategoryDiagnostic Testing Services
Description

Non-invasive diagnostic testing options enabling earlier detection and improved patient outcomes across oncology and infectious disease assays. Targeted at healthcare providers and physicians ordering precision diagnostics.

4Custom Sequencing Solutions
CategoryCustom NGS Services
Description

Tailored assays and bioinformatics pipelines for R&D and clinical translation. Targeted at diagnostic developers, pharma, and researchers requiring bespoke sequencing workflows.

5Bladder CARE™
CategoryDiagnostic Test (LDT)
Description

Urine-based bladder cancer test that measures methylation levels of three urothelial cancer-specific DNA biomarkers in a single qPCR reaction. Markedly outperforms traditional cytology. Targeted at urologists, oncologists, and healthcare providers screening/monitoring bladder cancer; has FDA Breakthrough Device Designation.

6iFOB (Immunoassay Fecal Occult Blood)
CategoryDiagnostic Test (LDT)
Description

Non-invasive fecal immunochemical test (FIT) for early detection of colorectal cancer through detection of fecal occult blood. False positive rate of 3.6%-5.1% versus 10.2%-13.4% for Cologuard®, with results in 1-3 days. Targeted at primary care physicians, gastroenterologists, and healthcare systems for programmatic CRC screening.

7GA-map® MHI GutHealth
CategoryDiagnostic Test (RUO)
Description

Microbiome-based diagnostic test quantifying antibiotic-induced gut microbiome imbalances using the Microbiome Health Index™ (MHI), utilizing 16S rRNA gene sequence analysis with MagPlex® microsphere and Luminex technology. Offered as a Research Use Only (RUO) test. Targeted at clinicians and researchers studying microbiome-related health conditions; results within 72 hours of sample receipt.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-21
Description

Strategic collaboration to validate AI-driven liquid biopsy assays (SPOT-MAS multi-cancer early detection test and K-4CARE precision oncology assay) for the U.S. market. Pangea conducts analytical and clinical validation at its CLIA/CAP-accredited facility in Irvine, California, while Gene Solutions provides SOPs, funding, and technical support from its CAP-accredited labs in Singapore and Vietnam. Upon successful validation, assays will be offered as Laboratory Developed Tests (LDTs).

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Partnership to launch GA-map® MHI GutHealth in the USA. Pangea Laboratory is the exclusive U.S.-based partner offering this microbiome-based diagnostic test as a Research Use Only (RUO) test. The test quantifies antibiotic-induced gut microbiome imbalances using the Microbiome Health Index™ (MHI).

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Partnership to introduce Bladder CARE™ Assay, enabling broader distribution of Pangea's proprietary bladder cancer diagnostic test.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration on Elexacaftor/Ivacaftor/Tezacaftor effect on microbial density and the microbiome.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration on human fecal microbiome and resistome after antibiotic treatment.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration on pediatric urine microbiome in health and disease.

7Kent State University
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Multiple research collaborations including skin microbiome studies between healthy and diabetic patients, wound healing case studies, and cross-linked extracellular matrix research.

pangealab.com
8Università degli Studi di Genova
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration on oral microbiome of periodontal implants.

pangealab.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration on diagnostic value of DNA methylation urine test for surveillance of non-muscle invasive bladder cancer.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Tempus Labs
TypeBroad incumbent
Description

AI-powered precision medicine company combining NGS, molecular profiling, and data analytics for oncology. Comparable to Pangea's AI/ML-driven multi-omics approach and precision oncology positioning, though Tempus operates at substantially larger scale with much greater funding.

TypeBroad incumbent
Description

Public molecular diagnostics company offering cell-free DNA testing across oncology, women's health, and organ health. Comparable to Pangea's molecular diagnostic and NGS-based testing capabilities, particularly in oncology precision medicine applications.

TypeDirect peer
Description

Molecular diagnostics and precision medicine company offering comprehensive tumor profiling, liquid biopsy, and AI-powered analytics. Comparable to Pangea's oncology focus, NGS capabilities, and AI/ML bioinformatics for multi-omics workflows.

TypeBroad incumbent
Description

Leading liquid biopsy and molecular diagnostics company offering oncology-focused NGS testing. Comparable to Pangea's SPOT-MAS/K-4CARE liquid biopsy validation partnership with Gene Solutions, though Guardant operates at significantly larger scale with established commercial channels.

TypeEmerging player
Description

Molecular diagnostics company offering non-invasive prenatal testing and oncology liquid biopsy. Comparable to Pangea's NGS-based diagnostic platform and multi-omics approach, with similar growth-stage characteristics and molecular diagnostics focus.

TypeBroad incumbent
Description

Clinical cancer genomics laboratory offering oncology testing services including NGS, molecular diagnostics, and clinical trial support. Directly comparable to Pangea's clinical development services, reference lab services, and oncology-focused diagnostic offerings.

TypeBroad incumbent
Description

Genomic diagnostics company focused on urologic cancers and other oncology indications, with tests including the Afirma genomic test. Particularly comparable to Pangea's Bladder CARE™ bladder cancer test, as both target urologic cancer diagnostics.

TypeDirect peer
Description

Direct competitor in non-invasive cancer screening, particularly with Cologuard® (multi-target stool DNA test for CRC screening) which Pangea's iFOB test directly competes against. Both companies offer stool-based colorectal cancer screening options to healthcare providers.

TypeEmerging player
Description

Molecular diagnostics company focused on oncology with proprietary tests for thyroid, pancreatic, and other cancers. Comparable to Pangea's LDT-based molecular diagnostic testing model and oncology-focused proprietary test portfolio.

TypeBroad incumbent
Description

Clinical laboratory offering comprehensive diagnostic testing including molecular diagnostics, genomics, and oncology testing. Comparable to Pangea's CLIA-certified clinical laboratory services and reference lab offerings, though at significantly larger scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pangea Laboratory

Molecular Diagnostics Laboratory Servicespangealab.com

Pangea Laboratory is a CLIA-certified, CAP-accredited next-generation sequencing and molecular diagnostics laboratory that provides clinical development services, reference lab work, and proprietary diagnostic tests to clinicians, researchers, and diagnostic developers.

What Pangea Laboratory does

Pangea Laboratory LLC is a CLIA-certified and CAP-accredited next-generation sequencing (NGS) and molecular diagnostics laboratory headquartered in Tustin, California, with an additional facility in Irvine. Founded in 2014 by Dr. Larry Jia — who also founded Zymo Research Corp and is credited with discovering the West Nile virus in North America — the company employs 101–250 people and operates as a private LLC. Its core technology stack combines NGS with multi-omics workflows, advanced bioinformatics, and AI/ML analytical tools for applications spanning epigenetics, microbiome analysis, and infectious disease.

The company serves three primary customer segments: clinicians and healthcare providers (oncologists, urologists, gastroenterologists, and primary care physicians) seeking precision diagnostic tests; researchers and academic institutions requiring high-throughput sequencing and validation; and pharmaceutical and diagnostic developers needing CLIA/CAP-grade analytical and clinical validation services. Its product portfolio includes proprietary laboratory developed tests (LDTs) — Bladder CARE™ (urine-based DNA methylation bladder cancer test with FDA Breakthrough Device Designation), iFOB (fecal immunochemical colorectal cancer screening with a reported 3.6%–5.1% false positive rate), and GA-map® MHI GutHealth (microbiome-based diagnostic licensed from Genetic Analysis AS) — alongside a forthcoming PrecisionBIOME™ NGS pathogen and antimicrobial resistance panel scheduled for Q2 2026. Strategic distribution is supported through partnerships with Unilabs (Bladder CARE™) and Gene Solutions (SPOT-MAS and K-4CARE liquid biopsy validation).

Pangea generates revenue through three primary streams: per-test transaction fees for laboratory testing services (CLIA/CAP reference lab work, iFOB, Bladder CARE™), professional services fees for clinical development and validation engagements with pharma and diagnostic developers, and licensing-equivalent economics from partnered LDT distribution. Pricing is quote-based and not publicly disclosed, though iFOB is positioned as substantially less expensive than colonoscopy or multi-target stool DNA alternatives (approximately 22× cheaper than Cologuard®). Go-to-market is primarily B2B enterprise field sales supported by digital marketing (website, LinkedIn, YouTube) and direct quote-based engagement with healthcare systems, hospital networks, and primary care physician groups. The company has no disclosed institutional investors, funding rounds, or revenue figures.

Pangea Laboratory firmographics

Firmographics
Name
Pangea Laboratory
Legal name
Pangea Laboratory LLC
Website
https://pangealab.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Pangea Laboratory is a CLIA-certified, CAP-accredited next-generation sequencing and molecular diagnostics laboratory that provides clinical development services, reference lab work, and proprietary diagnostic tests to clinicians, researchers, and diagnostic developers.
Ownership category
akta.pro rank

Pangea Laboratory industry classification

Industry
Product category
Molecular Diagnostics Laboratory Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Molecular diagnostics services
  • Next-generation sequencing
  • Clinical laboratory testing
  • Cancer screening diagnostics
  • Microbiome diagnostic testing

Where Pangea Laboratory is headquartered

Location

Headquarters

HQ city
Tustin
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Pangea Laboratory business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Laboratory Testing Services: CLIA/CAP-accredited laboratory providing diagnostic testing services including custom sequencing solutions, reference lab services, and clinical validation testing. Revenue generated from test processing fees.
  2. Clinical Development Services: Transforming innovative research into validated, clinically actionable insights through validated NGS-based diagnostics and precision testing for external partners.
  3. Diagnostic Products: Offering proprietary diagnostic tests including Bladder CARE™ for bladder cancer detection and iFOB for colorectal cancer screening as laboratory developed tests (LDTs).

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Pangea Laboratory product offering

Product offering

Core offering

Pangea Laboratory is a CLIA-certified and CAP-accredited Next-Generation Sequencing (NGS) diagnostic laboratory that delivers integrated services spanning custom sequencing solutions, clinical development, reference lab testing, and proprietary diagnostic assays. The company's menu includes Bladder CARE™ (urine-based DNA methylation bladder cancer test with FDA Breakthrough Device Designation), iFOB (fecal immunochemical colorectal cancer screening), GA-map® MHI GutHealth (microbiome-based gut health test), and PrecisionBIOME™ (NGS pathogen and antimicrobial resistance panel — coming Q2 2026). It serves clinicians, researchers, pharma companies, and diagnostic developers across oncology and infectious disease.

Product overview

Pangea Laboratory is a CLIA-certified and CAP-accredited NGS diagnostic laboratory offering an integrated suite of services spanning clinical development, reference lab services, and diagnostic laboratory testing. The company's product portfolio includes proprietary tests: Bladder CARE™ (urine-based DNA methylation bladder cancer test with FDA Breakthrough Device Designation), iFOB (fecal immunochemical test for colorectal cancer screening), GA-map® MHI GutHealth (microbiome-based gut health test in partnership with Genetic Analysis AS), and PrecisionBIOME™ (NGS platform for pathogen detection - coming Q2 2026). The company also provides custom sequencing solutions and serves as a reference laboratory for research and clinical applications.

Differentiator

Problem solved

Functional benefit

Brands

  • Bladder CARE: Urine-based DNA methylation test for bladder cancer detection, granted FDA Breakthrough Device Designation
  • PrecisionBIOME
  • iFOB
  • GA-map MHI GutHealth

Products and services

  • Clinical Development Services Translates innovative research into validated, clinically actionable insights through validated NGS-based diagnostics and precision testing, all within a CLIA/CAP environment. Targeted at diagnostic developers and pharma partners needing assay development, analytical and clinical validation.
  • Reference Lab Services High-throughput, high-quality sequencing and analysis services backed by rigorous quality controls and reproducible standards. Targeted at researchers, academic institutions, and clinicians needing reliable sequencing capacity.
  • Diagnostic Laboratory Services Non-invasive diagnostic testing options enabling earlier detection and improved patient outcomes across oncology and infectious disease assays. Targeted at healthcare providers and physicians ordering precision diagnostics.
  • Custom Sequencing Solutions Tailored assays and bioinformatics pipelines for R&D and clinical translation. Targeted at diagnostic developers, pharma, and researchers requiring bespoke sequencing workflows.
  • Bladder CARE™ Urine-based bladder cancer test that measures methylation levels of three urothelial cancer-specific DNA biomarkers in a single qPCR reaction. Markedly outperforms traditional cytology. Targeted at urologists, oncologists, and healthcare providers screening/monitoring bladder cancer; has FDA Breakthrough Device Designation.
  • iFOB (Immunoassay Fecal Occult Blood) Non-invasive fecal immunochemical test (FIT) for early detection of colorectal cancer through detection of fecal occult blood. False positive rate of 3.6%-5.1% versus 10.2%-13.4% for Cologuard®, with results in 1-3 days. Targeted at primary care physicians, gastroenterologists, and healthcare systems for programmatic CRC screening.
  • GA-map® MHI GutHealth Microbiome-based diagnostic test quantifying antibiotic-induced gut microbiome imbalances using the Microbiome Health Index™ (MHI), utilizing 16S rRNA gene sequence analysis with MagPlex® microsphere and Luminex technology. Offered as a Research Use Only (RUO) test. Targeted at clinicians and researchers studying microbiome-related health conditions; results within 72 hours of sample receipt.

Quantifiable outcome

  • Over 90% of colorectal cancer patients survive when detected at early stage
  • +3 more outcomes

Companies that use Pangea Laboratory

Customer profile

Segments4 records

Ideal customer profiles4 records

Pangea Laboratory technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Pangea Laboratory partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered flagship, core and minor.

  • Gene SolutionsflagshipStrategic or Co-development Partner · 21 January 2026Strategic collaboration to validate AI-driven liquid biopsy assays (SPOT-MAS multi-cancer early detection test and K-4CARE precision oncology assay) for the U.S. market. Pangea conducts analytical and clinical validation at its CLIA/CAP-accredited facility in Irvine, California, while Gene Solutions provides SOPs, funding, and technical support from its CAP-accredited labs in Singapore and Vietnam. Upon successful validation, assays will be offered as Laboratory Developed Tests (LDTs).
  • Genetic Analysis AScoreOEM/ Whitelabel/ Licensing PartnerPartnership to launch GA-map® MHI GutHealth in the USA. Pangea Laboratory is the exclusive U.S.-based partner offering this microbiome-based diagnostic test as a Research Use Only (RUO) test. The test quantifies antibiotic-induced gut microbiome imbalances using the Microbiome Health Index™ (MHI).
  • UnilabscoreChannel Partner/ Reseller/ DistributorPartnership to introduce Bladder CARE™ Assay, enabling broader distribution of Pangea's proprietary bladder cancer diagnostic test.
  • Miller Children's HospitalminorStrategic or Co-development PartnerResearch collaboration on Elexacaftor/Ivacaftor/Tezacaftor effect on microbial density and the microbiome.
  • Tuft's UniversityminorStrategic or Co-development PartnerResearch collaboration on human fecal microbiome and resistome after antibiotic treatment.
  • Children's Hospital of PittsburghminorStrategic or Co-development PartnerResearch collaboration on pediatric urine microbiome in health and disease.
  • Kent State UniversityminorStrategic or Co-development PartnerMultiple research collaborations including skin microbiome studies between healthy and diabetic patients, wound healing case studies, and cross-linked extracellular matrix research.
  • Università degli Studi di GenovaminorStrategic or Co-development PartnerResearch collaboration on oral microbiome of periodontal implants.
  • University of Southern California Norris Comprehensive Cancer CenterminorStrategic or Co-development PartnerResearch collaboration on diagnostic value of DNA methylation urine test for surveillance of non-muscle invasive bladder cancer.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Pangea Laboratory competitors and assessment

Company assessment

Broad incumbents

  • Tempus Labs: AI-powered precision medicine company combining NGS, molecular profiling, and data analytics for oncology. Comparable to Pangea's AI/ML-driven multi-omics approach and precision oncology positioning, though Tempus operates at substantially larger scale with much greater funding.
  • Natera: Public molecular diagnostics company offering cell-free DNA testing across oncology, women's health, and organ health. Comparable to Pangea's molecular diagnostic and NGS-based testing capabilities, particularly in oncology precision medicine applications.
  • Guardant Health: Leading liquid biopsy and molecular diagnostics company offering oncology-focused NGS testing. Comparable to Pangea's SPOT-MAS/K-4CARE liquid biopsy validation partnership with Gene Solutions, though Guardant operates at significantly larger scale with established commercial channels.
  • NeoGenomics: Clinical cancer genomics laboratory offering oncology testing services including NGS, molecular diagnostics, and clinical trial support. Directly comparable to Pangea's clinical development services, reference lab services, and oncology-focused diagnostic offerings.
  • Veracyte: Genomic diagnostics company focused on urologic cancers and other oncology indications, with tests including the Afirma genomic test. Particularly comparable to Pangea's Bladder CARE™ bladder cancer test, as both target urologic cancer diagnostics.
  • BioReference Laboratories (Sonic Healthcare): Clinical laboratory offering comprehensive diagnostic testing including molecular diagnostics, genomics, and oncology testing. Comparable to Pangea's CLIA-certified clinical laboratory services and reference lab offerings, though at significantly larger scale.

Direct peers

  • Caris Life Sciences: Molecular diagnostics and precision medicine company offering comprehensive tumor profiling, liquid biopsy, and AI-powered analytics. Comparable to Pangea's oncology focus, NGS capabilities, and AI/ML bioinformatics for multi-omics workflows.
  • Exact Sciences: Direct competitor in non-invasive cancer screening, particularly with Cologuard® (multi-target stool DNA test for CRC screening) which Pangea's iFOB test directly competes against. Both companies offer stool-based colorectal cancer screening options to healthcare providers.

Emerging players

  • BillionToOne: Molecular diagnostics company offering non-invasive prenatal testing and oncology liquid biopsy. Comparable to Pangea's NGS-based diagnostic platform and multi-omics approach, with similar growth-stage characteristics and molecular diagnostics focus.
  • Interpace Biosciences: Molecular diagnostics company focused on oncology with proprietary tests for thyroid, pancreatic, and other cancers. Comparable to Pangea's LDT-based molecular diagnostic testing model and oncology-focused proprietary test portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Pangea Laboratory social profiles

Digital presence

Pangea Laboratory compliance and trust

Trust signal

Compliance3 records

Pangea Laboratory financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pangea Laboratory leadership team

Management profile

Number of profiles

Profiles10 records

Pangea Laboratory funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pangea Laboratory M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pangea Laboratory

What does Pangea Laboratory do?

Pangea Laboratory is a CLIA-certified and CAP-accredited Next-Generation Sequencing (NGS) diagnostic laboratory that delivers integrated services spanning custom sequencing solutions, clinical development, reference lab testing, and proprietary diagnostic assays. The company's menu includes Bladder CARE™ (urine-based DNA methylation bladder cancer test with FDA Breakthrough Device Designation), iFOB (fecal immunochemical colorectal cancer screening), GA-map® MHI GutHealth (microbiome-based gut health test), and PrecisionBIOME™ (NGS pathogen and antimicrobial resistance panel — coming Q2 2026). It serves clinicians, researchers, pharma companies, and diagnostic developers across oncology and infectious disease.

Is Pangea Laboratory a public or private company?

Pangea Laboratory is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Pangea Laboratory founded?

Pangea Laboratory was founded in 2014. It employs 11 to 50 people.

Where is Pangea Laboratory based?

Pangea Laboratory is headquartered in Tustin, United States, in the North America region.

How does Pangea Laboratory make money?

Three revenue lines are on record. Laboratory Testing Services are the primary driver. The others are clinical Development Services and diagnostic Products.

Who are Pangea Laboratory's main competitors?

Broad incumbents on record are Tempus Labs, Natera, Guardant Health, NeoGenomics, Veracyte and BioReference Laboratories (Sonic Healthcare). Direct peers are Caris Life Sciences and Exact Sciences. Emerging players are BillionToOne and Interpace Biosciences.

Does Pangea Laboratory have an API?

No public API is recorded for Pangea Laboratory.

What industry is Pangea Laboratory in?

Pangea Laboratory's product category is Molecular Diagnostics Laboratory Services. Its primary akta.pro industry code is HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services, with a secondary code of HLAFAMAE, Molecular Diagnostics & Genomics Laboratories. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePangea Laboratory and Gene Solutions Establish Strategic Collaboration to Advance Cancer Diagnostics in the United StatesPangea Laboratory and Gene Solutions announced a strategic collaboration to validate AI-driven liquid biopsy assays for cancer detection in the U.S. market. Under the agreement, Pangea will conduct analytical and clinical validation of Gene Solutions' SPOT-MAS multi-cancer early detection test and K-4CARE precision oncology assay at its CLIA/CAP-accredited facility in Irvine, California, while Gene Solutions provides funding, standard operating procedures, and technical support from its CAP-accredited labs in Singapore and Vietnam. Upon successful validation, the assays are expected to be offered as laboratory developed tests (LDTs), bringing advanced cancer detection tools to U.S. patients.AcrofanGene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and CancerGene Solutions and Pangea Laboratory announced a strategic collaboration to validate liquid biopsy tests for cancer detection and monitoring in the U.S. They will focus on Gene Solutions' two flagship NGS tests, SPOT-MAS and K-4CARE, which utilize AI and multi-omics technologies.PR NewswireGene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.Gene Solutions and Pangea Laboratory have announced a strategic collaboration to advance U.S. clinical validation of Gene Solutions' AI-powered liquid biopsy assays for cancer detection, profiling, and monitoring. Under the agreement, Gene Solutions will provide SOPs, funding, and technical support from its CAP-accredited NGS laboratories in Singapore and Vietnam, while Pangea Laboratory will conduct all analytical and clinical validation at its U.S. facilities in Irvine, California. The collaboration's first phase will focus on validating Gene Solutions' two flagship tests—SPOT-MAS, a multi-cancer early detection blood test, and K-4CARE, a precision oncology assay with MRD monitoring capabilities—for the U.S. market under CLIA/CAP quality systems.YahooGene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.Gene Solutions and Pangea Laboratory announced a strategic collaboration to advance U.S. verification and clinical validation of Gene Solutions' liquid biopsy assays for cancer detection, profiling, and monitoring. Under the agreement, Gene Solutions will provide SOPs, funding, and technical support from its CAP-accredited NGS laboratories in Singapore and Vietnam, while Pangea Laboratory will oversee analytical and clinical validation at its U.S. facilities in Irvine, California. The first phase will prioritize validation of SPOT-MAS™, an AI-powered multi-cancer early detection blood test, and K-4CARE™, a precision oncology assay combining genomic and transcriptomic profiling with MRD detection, both within CLIA/CAP quality systems.PR NewswirePangea Laboratory Appoints John Moore as Chief Executive OfficerPangea Laboratory has appointed John Moore as its new Chief Executive Officer to lead the company's commercial and operational strategy. Moore will focus on scaling Pangea's non-invasive precision diagnostics, specifically advancing the market access for its FDA Breakthrough Designated Bladder CARE™ test.PR NewswirePangea Laboratory Partners with Unilabs to Introduce Bladder CARE™ Assay in Switzerland, Advancing Non-Invasive Cancer Diagnostics Across EuropePangea Laboratory partnered with Unilabs to introduce the Bladder CARE assay in Switzerland, with insurance coverage. The FDA-designated test detects bladder cancer and UTUC from urine with sensitivity, specificity, and NPV exceeding 93%. Plans include a broader European rollout.PR NewswirePangea Laboratory Receives FDA Breakthrough Device Designation for the Bladder CARE™ AssayPangea Laboratory received FDA Breakthrough Device Designation for its Bladder CARE assay, a urine-based test for bladder cancer and upper tract urothelial carcinoma. The assay reports 93.5% sensitivity and 92.6% specificity for bladder cancer, and 96.0% sensitivity and 88.0% specificity for UTUC. The company plans multicenter clinical trials toward premarket approval.PR NewswirePangea® Laboratory to License Bladder CARE™ Technology from Zymo ResearchPangea Laboratory has licensed the Bladder CARE technology from Zymo Research to commercialize a non-invasive, urine-based test for detecting bladder cancer. The licensing follows a pre-clinical study demonstrating the test's high sensitivity and specificity in analyzing urine samples for cancer DNA markers. This partnership aims to provide a cost-effective alternative to invasive cystoscopy procedures for patient monitoring and screening.